Liver Health — ALT/AST, Fatty Liver, Fructose

The VerdictHIGH CONVICTION

Your "normal" ALT lab range is two decades out of date, fructose isn't the villain, and 7% body weight loss does more for your liver than any supplement on the market.

Pull up your most recent bloodwork and read the ALT line. If it is above 30 (men) or above 19 (women), you are above the modern healthy threshold even if your lab report says "normal." Plug your numbers into a free FIB-4 calculator next.

The most surprising finding: the legacy ALT "normal range" of 40-55 U/L was derived from populations that already had undiagnosed fatty liver — the modern healthy threshold is 30 for men and 19 for women.
What most people get wrong: fructose itself isn't toxic. The vehicle is. A can of soda delivers 40 g in 15 minutes with no buffer. An apple delivers 10 g with fiber and water and slow digestion.
What to actually do about it: lose 7% of your body weight and stop drinking calories. ≥7% loss reverses fatty liver in most people. ≥10% reverses fibrosis in roughly half. No supplement comes close.

A fatty liver is your body's overflow car park. The liver was built to sit empty between meals so it can store glucose, build proteins, and clear toxins. When you eat more energy than you spend — over weeks, not over one weekend — the body parks extra fat in the liver because it has nowhere else to put it. Fructose drives this only when it's added on top of an already-full park (a daily soda); when you swap it in for the same calories, the park stays the same size.

The Practical Takeaway

Practical liver health steps illustration

1. Use the modern ALT cutoff: 30 for men, 19 for women

If your ALT is above those thresholds, calculate FIB-4 (free, takes thirty seconds — uses age, AST, ALT, and platelets). FIB-4 under 1.3 (under 2.0 if you are over 65) effectively rules out advanced fibrosis. If FIB-4 is indeterminate or elevated, transient elastography (FibroScan with CAP) is the next step. If FibroScan is indeterminate, MR elastography or hepatology referral.

2. Eliminate sugar-sweetened beverages and target a 7% body weight loss

This single combined action does more for fatty liver than any supplement, drug protocol, or "cleanse" available outside hepatology. Whole fruit is unrestricted. Mediterranean pattern beats low-fat at matched calories. Pace the loss at 0.5 to 1% body weight per week to avoid transient ALT spikes during fast fat mobilization.

3. Audit the supplement stack before assuming fatty liver

Before treating any unexplained ALT elevation as fatty liver, ask what is in the cabinet. Oral 17-alpha-alkylated anabolic steroids cause direct hepatotoxicity that can be life-threatening. High-dose green tea extract (≥800 mg EGCG/day) carries a small but real liver injury risk. Ashwagandha was added to the NIH LiverTox monograph in 2024 after a wave of cholestatic injury case reports. Multi-ingredient bodybuilding fat burners remain the leading single category in the US drug-induced liver injury registry. So can a single hard training session in the last 72 hours — AST is not liver-specific. Stop the suspect agent, wait six weeks, then re-test before any workup.

Pull up your most recent bloodwork and read the ALT line. If it is above 30 (men) or above 19 (women), you are above the modern healthy threshold even if your lab report says "normal."

Then plug your numbers into a free FIB-4 calculator. Modern liver-health screening starts with the right cutoff and a free fibrosis score, not an extra test or a supplement.

Takes less than 2 minutes. No equipment needed.

Conviction HIGH

Per-endpoint stratified — multiple sub-claims at independent conviction levels:

HIGH: ALT/AST as biomarkers; the Prati 2002 lower ULN (30 men / 19 women); visceral adiposity as the dominant driver; ≥7% weight loss reverses steatosis; hypercaloric SSB-fructose drives steatosis; iso-caloric fructose does not; FIB-4 + elastography as the screening cascade; oral 17α-alkylated AAS hepatotoxicity.
MODERATE-HIGH: Coffee inverse association with NAFLD progression; Mediterranean pattern superior to low-fat at matched calories.
MODERATE: High-dose EGCG (≥800 mg/day) idiosyncratic hepatotoxicity; ashwagandha-associated liver injury (case-series quality, LiverTox 2024); lean MASLD prevalence.
LOW / DEBUNKED: Vitamin E preventive use in healthy adults; milk thistle for healthy-adult liver protection; "liver detox" / "liver cleanse" products generally; single-point ALT/AST interpretation post-training.

What would change the iso-caloric fructose claim?

A well-powered, ≥12-week, double-blind, isocaloric crossover RCT in metabolically healthy adults (N≥150, ~25% of carbohydrate calories swapped from glucose to fructose, MRI-PDFF as primary endpoint) showing greater than 2 percentage points absolute increase in hepatic fat fraction over the glucose-controlled arm would shift this from HIGH to MODERATE and reopen the fructose-specific question.

What would change the coffee claim?

A pragmatic randomized trial of coffee assignment (≥1000 NAFLD patients over 3+ years, MR elastography fibrosis progression as primary endpoint) showing significant difference between zero and three-or-more cup arms would upgrade coffee from MODERATE-HIGH (observational) to HIGH (causal).

Go Deeper

Want evidence-scored answers to health questions like this — including the cardiometabolic marker quintet (cholesterol, blood pressure, HbA1c, CRP, and now liver)? Join The Verdict for free weekly reviews.

Subscribe — Free

Sources

Chong ASY et al., 2022, Adv Nutr. SR-MA of ~39 controlled trials. Hypercaloric fructose-containing sugars increase intrahepatocellular lipid (SMD 1.72) with high GRADE certainty. Iso-caloric substitution: no effect.
Chung M et al., 2014, Am J Clin Nutr. Foundational SR-MA establishing the iso-caloric vs hypercaloric distinction for fructose effects on liver health.
Zhang W et al., 2023, Nutr Metab (Lond). Observational meta-analysis (n=65,149). Added-fructose foods OR 1.31 for NAFLD prevalence; whole fruit not associated.
Kechagias S et al., 2008, Gut. RCT, healthy normal-weight adults. ~+1000 kcal/day surplus → ALT ~2.5x baseline within 4 weeks.
Romero-Gómez M et al., 2017, J Hepatol + EASL guidelines (2016, 2024 update). ≥7% body weight loss → 50–80% steatosis resolution; ≥10% → ~50% fibrosis regression.
Prati D et al., 2002, Ann Intern Med. Healthy-cohort derivation of the modern lower ALT ULN (≤30 U/L men, ≤19 U/L women).
Cantoral A et al., 2019, Nutrients (PMID 30823422). Cross-sectional, N=100 Mexican young adults. SSB + juice intake higher in MRI-confirmed NAFLD subgroup.
Sanyal AJ et al., 2010, NEJM (PIVENS). Vitamin E 800 IU/day in non-diabetic biopsy-proven NASH; significant ALT and steatosis reduction. Treatment indication, not preventive.
EFSA Panel, 2018, EFSA Journal. Risk threshold for high-dose green tea catechin idiosyncratic hepatotoxicity (≥800 mg EGCG/day).
NIH LiverTox 2024 update. Ashwagandha entry; case-series cholestatic drug-induced liver injury, generally recoverable on discontinuation.
Harrison SA et al., 2024, NEJM (MAESTRO-NASH). Resmetirom Phase 3 — first FDA-approved MASH therapy (March 2024).

Full source list with PMIDs and [cite-unverified] flags in the underlying RESEARCH.md.